JP2010507577A - トリアゾロピリダジンタンパク質キナーゼモジュレーター - Google Patents

トリアゾロピリダジンタンパク質キナーゼモジュレーター Download PDF

Info

Publication number
JP2010507577A
JP2010507577A JP2009533536A JP2009533536A JP2010507577A JP 2010507577 A JP2010507577 A JP 2010507577A JP 2009533536 A JP2009533536 A JP 2009533536A JP 2009533536 A JP2009533536 A JP 2009533536A JP 2010507577 A JP2010507577 A JP 2010507577A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
pyridinyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009533536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507577A5 (https=
Inventor
クリストファー・ロナルド・スミス
ピエール−イヴ・ブーノー
エリザベス・アン・ジェファーソン
パトリック・エス・リー
エドゥアルド・トレス
Original Assignee
エスジーエックス ファーマシューティカルズ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスジーエックス ファーマシューティカルズ、インコーポレイテッド filed Critical エスジーエックス ファーマシューティカルズ、インコーポレイテッド
Publication of JP2010507577A publication Critical patent/JP2010507577A/ja
Publication of JP2010507577A5 publication Critical patent/JP2010507577A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2009533536A 2006-10-23 2007-10-18 トリアゾロピリダジンタンパク質キナーゼモジュレーター Withdrawn JP2010507577A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87138406P 2006-12-21 2006-12-21
US91375207P 2007-04-24 2007-04-24
US95283307P 2007-07-30 2007-07-30
PCT/US2007/081832 WO2008051805A2 (en) 2006-10-23 2007-10-18 Triazolo-pyridazine protein kinase modulators

Publications (2)

Publication Number Publication Date
JP2010507577A true JP2010507577A (ja) 2010-03-11
JP2010507577A5 JP2010507577A5 (https=) 2010-12-02

Family

ID=39031065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533536A Withdrawn JP2010507577A (ja) 2006-10-23 2007-10-18 トリアゾロピリダジンタンパク質キナーゼモジュレーター

Country Status (16)

Country Link
US (1) US8071581B2 (https=)
EP (1) EP2081937B1 (https=)
JP (1) JP2010507577A (https=)
KR (1) KR101083177B1 (https=)
AU (1) AU2007309237B2 (https=)
BR (1) BRPI0717317A2 (https=)
CA (1) CA2667453A1 (https=)
DK (1) DK2081937T3 (https=)
EA (1) EA016527B1 (https=)
ES (1) ES2393132T3 (https=)
MX (1) MX2009004060A (https=)
PE (1) PE20081256A1 (https=)
PL (1) PL2081937T3 (https=)
PT (1) PT2081937E (https=)
TW (1) TW200833692A (https=)
WO (1) WO2008051805A2 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524385A (ja) * 2008-06-18 2011-09-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｅｔキナーゼ阻害剤としての３−（３−ピリミジン−２−イルベンジル）−１，２，４−トリアゾロ［４，３−ｂ］ピリダジン誘導体
JP2012512200A (ja) * 2008-12-18 2012-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ３−（３−ピリミジン−２−イルベンジル）−１，２，４−トリアゾロ［４，３−ｂ］ピリミジン誘導体
JP2013525371A (ja) * 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
JP2013527238A (ja) * 2010-06-01 2013-06-27 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
JP2015526486A (ja) * 2012-09-03 2015-09-10 クラウン バイオサイエンス インコーポレイテッド（台湾） 抗がん剤としての高選択性ｃ−Ｍｅｔ阻害剤
JP2016512209A (ja) * 2013-03-13 2016-04-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピン化合物の作製方法
JP2017503770A (ja) * 2013-12-09 2017-02-02 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性のモジュレーターとしてのトリアゾロピリダジン誘導体

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP2674428B1 (en) 2006-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
ME02372B (me) 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
WO2009143211A2 (en) * 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
JP2012509342A (ja) * 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
CA2744563A1 (en) * 2008-12-12 2010-06-17 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
ES2427917T3 (es) * 2009-02-10 2013-11-04 Astrazeneca Ab Derivados de triazolo [4,3-b] piridazina y sus usos para el cáncer de próstata
US8865719B2 (en) 2009-03-09 2014-10-21 The Regents Of The University Of California Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
EP3795573B1 (en) * 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
US9586963B2 (en) 2011-09-27 2017-03-07 Genfit Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
EP2831073B1 (en) 2012-03-30 2020-12-09 Rhizen Pharmaceuticals S.A. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
ES2619610T3 (es) 2012-10-16 2017-06-26 Janssen Pharmaceutica Nv Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo
US9846345B2 (en) 2013-02-28 2017-12-19 Empire Technology Development Llc Colored pigment particles for electrophoretic displays
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
SG11201506687RA (en) 2013-03-15 2015-09-29 Plexxikon Inc Heterocyclic compounds and uses thereof
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
WO2015134854A2 (en) * 2014-03-06 2015-09-11 Oyagen, Inc. Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics
RU2744460C2 (ru) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
JP2018501279A (ja) 2014-12-31 2018-01-18 アンギオン バイオメディカ コーポレイション 疾患を治療するための方法及び薬剤
BR112017020952A2 (pt) * 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
AR105392A1 (es) 2015-07-20 2017-09-27 Genzyme Corp Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
JP7675519B2 (ja) 2017-10-13 2025-05-13 オプナ バイオ ソシエテ アノニム キナーゼを調節するための化合物の固体形態
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN113861198B (zh) * 2020-06-30 2024-08-02 上海医药集团股份有限公司 咪唑并[4,5-b]吡嗪类化合物、其制备方法及应用
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083139A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
WO2002083675A2 (en) 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
WO2003014649A1 (en) * 2001-08-10 2003-02-20 Yokohama Tlo Company Ltd. Heat transfer device
HUE030390T2 (en) * 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
JP2009538899A (ja) * 2006-05-30 2009-11-12 ファイザー・プロダクツ・インク トリアゾロピリダジン誘導体
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524385A (ja) * 2008-06-18 2011-09-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｅｔキナーゼ阻害剤としての３−（３−ピリミジン−２−イルベンジル）−１，２，４−トリアゾロ［４，３−ｂ］ピリダジン誘導体
JP2012512200A (ja) * 2008-12-18 2012-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ３−（３−ピリミジン−２−イルベンジル）−１，２，４−トリアゾロ［４，３−ｂ］ピリミジン誘導体
JP2013525371A (ja) * 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
JP2013527238A (ja) * 2010-06-01 2013-06-27 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
JP2015526486A (ja) * 2012-09-03 2015-09-10 クラウン バイオサイエンス インコーポレイテッド（台湾） 抗がん剤としての高選択性ｃ−Ｍｅｔ阻害剤
JP2016512209A (ja) * 2013-03-13 2016-04-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピン化合物の作製方法
JP2018008959A (ja) * 2013-03-13 2018-01-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピン化合物の作製方法
KR101871133B1 (ko) 2013-03-13 2018-06-25 에프. 호프만-라 로슈 아게 벤즈옥사제핀 화합물의 제조 방법
JP2017503770A (ja) * 2013-12-09 2017-02-02 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性のモジュレーターとしてのトリアゾロピリダジン誘導体

Also Published As

Publication number Publication date
US8071581B2 (en) 2011-12-06
MX2009004060A (es) 2009-06-19
WO2008051805A3 (en) 2008-07-10
PT2081937E (pt) 2012-10-15
WO2008051805A2 (en) 2008-05-02
PE20081256A1 (es) 2008-10-13
US20100120739A1 (en) 2010-05-13
TW200833692A (en) 2008-08-16
EP2081937A2 (en) 2009-07-29
EP2081937B1 (en) 2012-09-12
PL2081937T3 (pl) 2013-01-31
BRPI0717317A2 (pt) 2013-10-22
CA2667453A1 (en) 2008-05-02
ES2393132T3 (es) 2012-12-18
DK2081937T3 (da) 2012-10-01
KR101083177B1 (ko) 2011-11-11
AU2007309237B2 (en) 2012-03-22
EA016527B1 (ru) 2012-05-30
KR20090069303A (ko) 2009-06-30
EA200970402A1 (ru) 2009-10-30
AU2007309237A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
KR101083177B1 (ko) 트리아졸로-피리다진 단백질 키나제 조정제
JP5378222B2 (ja) タンパク質キナーゼ調節物質としての二環式トリアゾール
US20240366608A1 (en) Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
JP6785819B2 (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
AU2015271837B2 (en) Tank-binding kinase inhibitor compounds
TWI494314B (zh) ５,７－取代的－咪唑并［１,２－ｃ］嘧啶
CN101558070A (zh) 三唑并哒嗪蛋白激酶调节剂
US20220098203A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
US20220251081A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
JP5992096B2 (ja) Ｐｄｅ１０阻害剤としてのトリアゾロ化合物
CN104363908B (zh) 吡咯烷基杂环类
AU2023380028A1 (en) Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101015

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121120